Clinical Trial Update: Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of trastuzumab emtansine in patients with HER2-equivocal breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: Jenny C. Chang, MD | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN